Real-World Treatment Patterns Among Patients Newly Diagnosed With Chronic Inflammatory Demyelinating Polyneuropathy in the United States
Author(s)
SWAPNA KARKARE, MS1, CECILE BLEIN, PhD2, Arash Mahajerin, MD, MSCr1, Larisa Gofman, PhD3, Mai Sato, PhD4, Tania Banerji, MPH, MS5, Yachendra Challa, B.Tech6, Amit Goyal, MBA7.
1argenx, Boston, MA, USA, 2Argenx, Zwijnaarde, Belgium, 3Medical & Evidence, ZS Associates, Lincroft, NJ, USA, 4ZS Associates, New York, NY, USA, 5Medical & Evidence, ZS Associates, Bethesda, MD, USA, 6ZS Associates, Bangalore, India, 7ZS Associates, Lawrence Township, NJ, USA.
1argenx, Boston, MA, USA, 2Argenx, Zwijnaarde, Belgium, 3Medical & Evidence, ZS Associates, Lincroft, NJ, USA, 4ZS Associates, New York, NY, USA, 5Medical & Evidence, ZS Associates, Bethesda, MD, USA, 6ZS Associates, Bangalore, India, 7ZS Associates, Lawrence Township, NJ, USA.
OBJECTIVES: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare autoimmune inflammatory disorder of the peripheral nervous system. Given limited real-world evidence on the patient journey following an incident CIDP diagnosis, this analysis aimed to characterize detailed treatment patterns and sequencing for this US patient population.
METHODS: A retrospective cohort study was conducted using Optum’s de-identified Market Clarity data® (Optum® Market Clarity) from January 2016 - March 2024. Adult patients with CIDP were identified based on having: (1) ≥2 CIDP diagnosis (Dx) claims, ≥30-≤365 apart; (2) ≥1 nerve conduction test ≤90 days before or after first observed CIDP Dx, with ≥1 CIDP Dx following it within 365 days (first observed Dx claim is index date). Patients were also required to have ≥1 and ≥2 years of continuous enrollment pre- and post-index date, respectively, and no CIDP Dx prior to index, during all available look-back data. Treatment patterns were reported over a 2-year follow-up period.
RESULTS: Among 917 adult patients newly diagnosed with CIDP (mean age 60 years; 38% female), 684 (75%) received >1 treatment of the following during the 2-year follow-up: steroids, immunoglobulin [Ig], biologics, non-steroidal immunosuppressive therapies and plasmapheresis. Of these 684 patients, 659 (96%) had ≥1 LOT and 369 (54%) had ≥2 LOTs. Patients started their first LOT on average 110 days after index and were treated with above-mentioned treatments for an average of 48 weeks during the 2-year follow-up. First-line treatments were predominantly Ig monotherapy (58%; mean duration: 253 days) or steroid monotherapy (34%; 85 days). Second-line therapies were predominantly steroid monotherapy (35%; 65 days) or steroid + Ig combination (33%; 83 days).
CONCLUSIONS: Most patients newly diagnosed with CIDP initiated treatment with Ig or steroids, but over 50% required a second LOT within 2 years post-diagnosis, highlighting potential unmet clinical needs.
METHODS: A retrospective cohort study was conducted using Optum’s de-identified Market Clarity data® (Optum® Market Clarity) from January 2016 - March 2024. Adult patients with CIDP were identified based on having: (1) ≥2 CIDP diagnosis (Dx) claims, ≥30-≤365 apart; (2) ≥1 nerve conduction test ≤90 days before or after first observed CIDP Dx, with ≥1 CIDP Dx following it within 365 days (first observed Dx claim is index date). Patients were also required to have ≥1 and ≥2 years of continuous enrollment pre- and post-index date, respectively, and no CIDP Dx prior to index, during all available look-back data. Treatment patterns were reported over a 2-year follow-up period.
RESULTS: Among 917 adult patients newly diagnosed with CIDP (mean age 60 years; 38% female), 684 (75%) received >1 treatment of the following during the 2-year follow-up: steroids, immunoglobulin [Ig], biologics, non-steroidal immunosuppressive therapies and plasmapheresis. Of these 684 patients, 659 (96%) had ≥1 LOT and 369 (54%) had ≥2 LOTs. Patients started their first LOT on average 110 days after index and were treated with above-mentioned treatments for an average of 48 weeks during the 2-year follow-up. First-line treatments were predominantly Ig monotherapy (58%; mean duration: 253 days) or steroid monotherapy (34%; 85 days). Second-line therapies were predominantly steroid monotherapy (35%; 65 days) or steroid + Ig combination (33%; 83 days).
CONCLUSIONS: Most patients newly diagnosed with CIDP initiated treatment with Ig or steroids, but over 50% required a second LOT within 2 years post-diagnosis, highlighting potential unmet clinical needs.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
SA79
Topic
Health Service Delivery & Process of Care, Study Approaches
Disease
Neurological Disorders, No Additional Disease & Conditions/Specialized Treatment Areas